Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORG1833: osimertinib plus ramucirumab versus osimertinib in untreated EGFR-mutated nonsquamous non-small cell lung cancer
jRCT2080224085Phase 2Completed
- Sponsor
- Kanagawa Prefectural Cancer Center
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib monotherapy with Osimertinib plus ramucirumab (2 arms). Started Oct 2018; status: completed.
02
Drugs
osimertinibramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224085.